Company Overview More
Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. It offers Innatal, a noninvasive prenatal screening test offered to women early in pregnancy to screen for chromosome abnormalities, such as down syndrome, trisomy 18, trisomy 13, and sex chromosome disorders through the analysis of cell-free DNA; Preparent that screens for carrier status of hereditary diseases prior to or early in pregnancy; and Riscover, a hereditary cancer screen that analyzes 31 genes associated with inherited risk of 12 types of cancers, including the BRCA1/2 genes for hereditary breast, ovarian, colorectal, endometrial, pancreatic, and other cancer syndromes, as well as for the five genes associated with Lynch syndrome. The company also provides Resura, a noninvasive prenatal test for families at risk for rare single gene disorders; and Preecludia, a preeclampsia rule-out test. In addition, it offers anatomic and molecular pathology tests, and COVID-19 PCR testing services, as well as test products that includes chromosomal microarray for pregnancy loss, which evaluates the genetic cause of miscarriage; maternal serum screening for chromosomal disorders; and preimplantation genetic testing for use with artificial reproductive technologies. Further, the company develops therapeutic solutions for gastrointestinal-related disorders, such as PGN-001, PGN-300, PGN-600, and PGN-OB2. It also owns and operates laboratory. Progenity, Inc. was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.
CEO: Mohanty, Aditya P.
Market: NASDAQ
Futu Hot List
USHKCN
Trade HeatSearch HeatNews Heat
SymbolLatest Price% Chg

Loading...

Moomoo > Quotes > PROG Progenity > Company Executives
PROG Progenity
3.640-0.110-2.93%
Post Mkt Price
3.540-0.1-2.75%
NamePositionSalaryService DateEducationAgeGenderUpdated
Mr. Aditya P. MohantyChief Executive Officer and Director------54male2021/11/09
Mr. Eric d’EsparbesChief Financial Officer and Principal Accounting Officer2.34M----54male2021/11/09
Mr. Damon SilvestryChief Operating Officer1.82M----53male2021/04/15
Mr. Sami ShihabiChief Commercial Officer------49male2021/04/15
Mr. Matthew CooperChief Scientific Officer------48male2021/04/15
Mr. Troy SeelyeChief Information Officer------57male2021/04/15
Mr. Hutan HashemiChief Compliance Officer------42male2021/04/15
Mr. Clarke NeumannGeneral Counsel and Secretary------57male2021/04/15
Mr. George GianakopoulosSenior Vice President, Sales------59male2021/04/15
Ms. Surbhi SarnaDirector------35female2021/06/30
Ms. Jill HoweDirector------45female2021/11/04
Mr. Samuel R. Nussbaum, M.D.Independent Director209.93K----72male2021/04/15
Ms. Lynne PowellIndependent Director207.93K----54female2021/04/15
Mr. Brian L. KotzinIndependent Director192.57K----72male2021/04/15
Mr. Jeffrey D. AlterLead Independent Director241.48K----58male2021/04/15
Mr. Jeffrey A. FerrellIndependent Director------46male2021/04/15